Terconazole microbiology: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{XXXXX}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TERAZOL 7 (TERCONAZOLE) CREAM TERAZOL 3 (TERCONAZOLE) ...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Microbiology== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TERAZOL 7 (TERCONAZOLE) CREAM TERAZOL 3 (TERCONAZOLE) CREAM TERAZOL 3 (TERCONAZOLE) SUPPOSITORY [JANSSEN PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f2626b3-6053-4f7a-bc5d-78e30d983f90 | publisher = | date = | accessdate = }}</ref> | Terconazole exhibits '''fungicida'''l activity in vitro against [[Candida albicans]]. Antifungal activity has also been demonstrated against other fungi. The MIC values of terconazole against most [[Lactobacillus]] spp. typically found in the human vagina were ≥128 mcg/mL; therefore these beneficial bacteria are '''not''' affected by drug treatment. | ||
The exact pharmacologic mode of action of terconazole is uncertain; however, it may exert its antifungal activity by the disruption of normal fungal cell membrane permeability. No resistance to terconazole has developed during successive passages of C. albicans.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TERAZOL 7 (TERCONAZOLE) CREAM TERAZOL 3 (TERCONAZOLE) CREAM TERAZOL 3 (TERCONAZOLE) SUPPOSITORY [JANSSEN PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f2626b3-6053-4f7a-bc5d-78e30d983f90 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Revision as of 11:50, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Microbiology
Terconazole exhibits fungicidal activity in vitro against Candida albicans. Antifungal activity has also been demonstrated against other fungi. The MIC values of terconazole against most Lactobacillus spp. typically found in the human vagina were ≥128 mcg/mL; therefore these beneficial bacteria are not affected by drug treatment.
The exact pharmacologic mode of action of terconazole is uncertain; however, it may exert its antifungal activity by the disruption of normal fungal cell membrane permeability. No resistance to terconazole has developed during successive passages of C. albicans.[1]
References
Adapted from the FDA Package Insert.